Methadone in cancer pain

European Journal of Pain

Volumn 1, Issue 2, 1997, Pages 77-83

  Mercadante, S ^a  

^a SAMOT Onlus   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0002114049     PISSN: 10903801     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1090-3801(97)90064-1     Document Type: Review

References (51)

1. Bohrer H, Smith H. Local toxicity with subcutaneous methadone. Pain 1992; 50: 373.
2. Bruera E, Fainsinger R, Moore M, Thibault E, Spoldi V, Ventafridda V. Clinical note: local toxicity with subcutaneous methadone - experience of two centers. Pain 1991; 45: 141-143.
3. Bruera E, Schoeller T, Fainsinger RL, Kastelan C. Custommade suppositories of methadone for severe cancer pain. J Pain Symptom Manage 1992; 7: 372-374.
4. Bruera E, Watanabe S, Fainsinger RL, Spachynski K, Suarez-Almazor M, Inturrisi C. Custom-made capsules and suppositories of methadone for patients on high dose opioids for cancer pain. Pain 1995; 62: 141-146.
5. Crews JC, Sweeney NJ, Denson DD. Clinical efficacy of methadone in patients refractory to other mu-opioid receptor agonist for management of terminal cancer pain. Cancer 1993; 72: 2266-2272.
6. De Conno F, Groff L, Brunelli C, Zecca E, Ventafridda V, Ripamonti C. Analgesic efficacy and tolerability or oral methadone in 196 patients with advanced cancer related pain. J Clin Oncol 1996; 14: 2836-2842.
7. de Leon-Casasola OA, Lema MJ. Postoperative epidural opioid analgesia: what are the choices? Anesth Analg 1996; 83: 867-875.
8. Ebert B, Andersen S, Krogsgaard-Larsen P. Ketobemidone, methadone and pethidine are non-competitive N-methyl-D-aspartate (NMDA) antagonists in the rat cortex and spinal cord. Neurosci Lett 1995; 187: 165-168.
9. Fainsinger R, Schoeller T, Bruera E. Methadone in the management of cancer pain: a review. Pain 1993; 52: 137-147.
10. Galer BS, Coyle N, Pasternak GW, Portenoy RK. Individual variability in the response to different opioids: report of five cases. Pain 1992; 49: 87-91.
11. Goldstein A. Blind comparison of once-daily and twicedaily dosage schedules in a methadone program. Clin Pharmacol Ther 1972; 13: 59-63.
12. Gourlay GK, Willis RJ, Lamberty J. A double-blind comparison of the effects of methadone and morphine in postoperative pain control. Anesthesiology 1986; 42: 322-327.
13. Gourlay GK, Plummer JL, Cherry DA, Cousins MJ. Does intravenous methadone provide longer lasting analgesia than intravenous morphine? Pain 1990; 42: 383-384.
14. Grochow L, Sheidler V, Grossman S, Green L, Enterline J. Does intravenous methadone provide longer lasting analgesia than intravenous morphine? A randomized, double-blind study. Pain 1989; 38: 151-157.
15. Hanks GW, De Conno F, Ripamonti C, Ventafridda V, Hanna M, McQuay HJ. Mercadante S, Meynadier J, Poulain P, Roca i Casas J, Sawe J, Twycross RG, Vainio A, Zech D. Morphine in cancer pain: modes of administration. Br Med J 1996; 312: 823-826.
16. Hiltunen AJ, Lafolie P, Martel J, Ottosson EC, Boreus LO, Beck O, Borg S, Hjemdahl P. Subjective and objective symptoms in relation to plasma methadone concentration in methadone patients. Psychopharmacology 1995; 118: 122-126.
17. Horns WH, Rado M, Goldstein A. Plasma levels and symptom complaints in patients maintained on daily dosage of methadone hydrochloride. Clin Pharmacol Ther 1975; 17: 636-648.
18. Hunt G, Bruera E. Respiratory depression in a patient receiving oral methadone for cancer pain. J Pain Symptom Manage 1995; 10: 401-404.
19. Inturissi CE, Colburn WA. Pharmacokinetics of methadone. In: Foley KM, Inturrisi CE, editors. Advances, in Pain Research and Therapy. New York, Raven Press 1986: 191-199.
20. Inturrisi CE, Colburn WA, Kaiko RF, Houde RW, Foley KM. Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain. Clin Pharmacol Ther 1987; 41: 392-401.
21. Ivarsson M, Neil A. Differences in efficacies between morphine and methadone demonstrated in the guinea pig ileum: a possible explanation for previous observations on incomplete opioid cross-tolerance. Pharmacol Toxicol 1989; 65: 368-371.
22. Jacobson L, Chabal C, Brody MG et al. Intrathecal methadone and morphine for postoperative analgesia: a comparison of the efficacy, duration and side effects. Anesthesiology 1989; 70: 742-746.
23. Jacobson L, Chabal C, Brody MC, Ward RJ, Wasse L. Intrathecal methadone: a dose-response study and comparison with intrathecal morphine 0.5 mg. Pain 1990; 43: 141-148.
24. Kreek MJ, Schecter AJ, Gutjahr CL, Hecht M. Methadone use in patients with chronic renal disease. Drug Alcohol Depend 1980; 5: 197-205.
25. Kreek MJ, Bencsath FA, Fanizza A, Field FH. Effects of liver disease on fecal excretion of methadone and its unconjugated metabolites in maintenance patients. Biom Mass Spectrometry 1983; 10: 544-549.
26. Kristensen K, Blemmer T, Angelo HR, Christrup LL, Drenck NE, Rasmussen SN, Sjogren P. Stereoselective pharmacokinetics of methadone in chronic pain patients. Ther Drug Monitor 1996; 18: 221-227.
27. Leng G, Finnegan MJ. Successful use of methadone in nociceptive cancer pain unresponsive to morphine. Palliat Med 1994; 8: 153-155.
28. MacDonald N, Der L, Allan S, Champion P. Opioid hyperexcitability: the application of alternate opioid therapy. Pain 1993; 53: 353-355.
29. Mao J, Price D, Mayer DJ. Experimental neuropathy reduces the antinociceptive effects of morphine: implications for common intracellular mechanisms involved in morphine tolerance and neuropathic pain. Pain 1995; 61: 353-364.
30. Mercadante S, Sapio M, Serretta R, Caligara M. Patientcontrolled analgesia with oral methadone in cancer patients: preliminary report. Ann Oncol 1996; 7: 613-618.
31. Mercadante S, Sapio M, Serretta R. Treatment of pain in chronic bowel subobstruction with self-administration of methadone. Support Care Cancer 1997 (in press).
32. Morley JS, Watt JWG, Wells JC, Miles JB, Finnegan MJ, Leng G. Methadone in pain uncontrolled by morphine. Lancet 1993; 342: 1243.
33. Nilsson MI, Widelov E, Meresaar U et al. Effect of urinary pH on the disposition of methadone in man. Eur J Clin Pharmacol 1982; 22: 337-342.
34. Nilsson MI, Anggard E, Holmstrand J, Gunne LM. Pharmacokinetics of methadone during maintenance treatment: adaptive changes during the induction phase. Eur J Clin Pharmacol 1982; 22: 343-349.
35. Neil A. Morphine- and methadone-tolerant mice differ in cross-tolerance to other opiates. Naunyn-Schmiedeberg's Arch Pharmacol 1982; 320: 50-53.
36. O'Neill WM, Onen TS. Methadone therapy. Lancet 1993; 341: 1277-1278.
37. Paalzow L, Nilsson L, Stenberg P. Pharmacokinetic basis for optimal methadone treatment of pain in cancer patients. Acta Anaesthesiol Scand 1982; 74: 55-58.
38. Plummer JL, Gourlay GK, Cherry DA, Cousins MJ. Estimation of methadone clearance: application in the management of cancer pain. Pain 1988; 33: 313-322.
39. Portenoy RK, Foley KM, Stulman J, Khan E, Adelhardt J, Layman M et al. Plasma morphine and morphine-6-glucuronide during chronic morphine therapy for cancer pain: plasma profiles, steady-state concentrations and the consequences of renal failure. Pain 1991; 47: 13-19.
40. Portnow JM, Corbett RJ. Oral methadone for relief of chronic pain from cancer. New Engl J Med 1982; 306: 889-990.
41. Ralphs JA, Williams ACC, Richardson PH, Pither CH, Nicholas MK. Opiate reduction in chronic pain patients: a comparison of patient-controlled reduction and staff controlled cocktail methods. Pain 1994; 56: 279-288.
42. Richlin DM, Jamron LM, Novick NL. Cancer pain control with a combination of methadone, amitriptyline and nonnarcotic analgesic therapy: a case series analysis. J Pain Symptom Manage 1987; 2: 89-94.
43. Ripamonti C, Zeca E, Brunelli C, Rizzio E, Saita L, Lodi F, De Conno F. Rectal methadone in cancer patients with pain. A preliminary clinical and pharmacokinetic study. Ann Oncol 1995; 6: 841-843.
44. Sawe J, Hansen J, Ginman C, Hartvig P, Jacobson PA, Nilsson MI, Rane A, Anggard E. Patient-controlled dose regimen of methadone for chronic cancer pain. Br Med J 1981; 282: 771-779.
45. Sawe J. High-dose morphine and methadone in cancer patients. Clin Pharmacokin 1986; 11: 87-106.
46. Symonds P. Methadone and the elderly. Br Med J 1977; 1: 512.
47. Thomas Z, Bruera E. Use of methadone in a highly tolerant patient receiving parenteral hydromorphone. J Pain Symptom Manage 1995; 10: 315-317.
48. Ventafridda V, Ripamonti C, Bianchi M et al. A randomized study on oral administration of morphine and methadone in the treatment of cancer pain. J Pain Symptom Manage 1986; 1: 203-207.
49. Verebely K, Volavka J, Mule S, Resnick R. Methadone in man: pharmacokinetic and excretion studies in acute and chronic treatment. Clin Pharmacol Ther 1975; 18: 180-190.
50. Vigano A, Fan D, Bruera E. Individualized use of methadone and opioid rotation in the comprehensive management of cancer pain associated with poor prognostic indicators. Pain 1996; 67: 115-119.
51. Weinberg DS, Inturrisi CE, Reidenberg et al. Sublingual absorption of selected opioid analgesics. Clin Pharmacol Ther 1988; 44: 335-342.